Lupin Settles Patent Dispute With U.S. Makers Of Glumetza Diabetes Drug
This article was originally published in PharmAsia News
Lupin Pharmaceuticals agreed to a patent-settlement with two U.S.-based companies, Santarus and Depomed, giving Lupin a chance at an early launch of a generic of the diabetes drug, Glumetza (metformin).
You may also be interested in...
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Device Week, 12 December 2019 – Global Insulin Pump Market Will Face Fierce Rivalry Among Major Players In 2020
In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about her latest in-depth Market Intel story, the first part of a two-part series focusing on the competitive landscape of the global insulin pump market.
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its CEO tells Scrip.